Search results
Showing 436 to 450 of 1257 results for pathway
Optilume for treating recurrent bulbar urethral strictures (HTG649)
Evidence-based recommendations on Optilume for treating recurrent bulbar urethral strictures.
Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)
NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .
We have moved Diagnostics guidance 56 to become HealthTech guidance 690. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
Show all sections
Evidence-based recommendations on tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). This involves cutting the horizontal muscles of the eye (which move the eye from side to side) and reattaching them at the same place.
View recommendations for HTG191Show all sections
Sections for HTG191
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
NICE has developed a medtech innovation briefing (MIB) on Coban 2 for venous leg ulcers .
This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.
View quality statements for QS49Show all sections
Sections for QS49
- Quality statements
- Quality statement 1: Personal preparation for surgery
- Quality statement 2: Antibiotic prophylaxis
- Quality statement 3: Patient temperature
- Quality statement 4: Intraoperative staff practices
- Quality statement 5: Information and advice on wound care
- Quality statement 6: Treatment of surgical site infection
- Quality statement 7: Surveillance
End of life care for infants, children and young people (QS160)
This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS160Show all sections
Sections for QS160
- Quality statements
- Quality statement 1: Advance care plan
- Quality statement 2: Named medical specialist
- Quality statement 3: Emotional and psychological support
- Quality statement 4: Specialist paediatric palliative care team
- Quality statement 5: Support for grief and loss for parents or carers
- Quality statement 6: Care at home
- About this quality standard
Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.
Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.
View recommendations for TA515Show all sections
Midostaurin for treating advanced systemic mastocytosis (TA728)
Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.
Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.